Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19–induced and/or aggravated ME/CFS
Open Access
- 9 January 2025
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2886-2899
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (501875662)
- Miltenyi Biotec
This publication has 66 references indexed in Scilit:
- Cognitive Symptoms of Post–COVID-19 Condition and Daily FunctioningJAMA Network Open, 2024
- Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptorsAutoimmunity Reviews, 2023
- Overview of autoantibodies in COVID‐19 convalescentsJournal of Medical Virology, 2023
- Persistent circulation of soluble and extracellular vesicle‐linked Spike protein in individuals with postacute sequelae of COVID‐19Journal of Medical Virology, 2023
- Herpesvirus infections and post-COVID-19 manifestations: a pilot observational studyRheumatology International, 2022
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020
- Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?Human Genetics, 2020
- Effectiveness of different immunoadsorption columns for anti-A/B antibody depletionAtherosclerosis Supplements, 2019
- Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseasesSeminars in Immunopathology, 2014
- Immunoregulation by Naturally Occurring and Disease-Associated Autoantibodies2012